Amgen’s KRAS G12C Inhibitor Shows Deep, Durable Efficacy In Lung Cancer

 
• By Mandy Jackson

Results from the Phase II CodeBreak 100 study of sotorasib presented at the World Conference on Lung Cancer were included in Amgen’s applications for approvals in the US, EU and other countries. 

Pulmonology vector illustration
Amgen continues to explore monotherapy, combinations and biomarkers for sotorasib in lung cancer • Source: Shutterstock

More from Clinical Trials

More from R&D